Gliknik Inc., a privately held biopharmaceuticals company, today announced that researchers from University of Pennsylvania and University of Maryland presented at the American Society of Hematology Annual Meeting interim clinical data from a study that included treatment of high-risk multiple myeloma patients with Gliknik's MAGE-A3 ... (more)
http://www.drugs.com/clinical_trials/gliknik-announces-interim-clinical-data-immunomodulator-candidate-multiple-myeloma-patients-14925.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+Drugscom-ClinicalTrials+%28Drugs.com+-+Clinical+Trials%29
http://www.drugs.com/clinical_trials/gliknik-announces-interim-clinical-data-immunomodulator-candidate-multiple-myeloma-patients-14925.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+Drugscom-ClinicalTrials+%28Drugs.com+-+Clinical+Trials%29
No comments:
Post a Comment